<DOC>
	<DOCNO>NCT00093600</DOCNO>
	<brief_summary>RATIONALE : PKC412 may stop growth cancer cell block enzymes necessary growth . It may also increase effectiveness daunorubicin cytarabine make cancer cell sensitive drug . Drugs use chemotherapy , daunorubicin cytarabine , work different way stop cancer cell divide stop grow die . Combining PKC412 chemotherapy may kill cancer cell . PURPOSE : This phase I trial study side effect best way give PKC412 give either together daunorubicin cytarabine treat patient newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>PKC412 , Daunorubicin , Cytarabine Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability PKC412 administer sequentially concurrently induction chemotherapy comprise daunorubicin cytarabine follow consolidation therapy comprise high-dose cytarabine patient newly diagnose acute myeloid leukemia . - Compare pharmacokinetics regimens patient . Secondary - Determine efficacy regimen , term response rate , disease-free survival , overall survival , patient . - Correlate genetic variation drug metabolism gene , leukemia gene , drug target gene response patient treat regimen . OUTLINE : This open-label , multicenter study . Patients alternately assign 1 2 induction treatment group . - Induction therapy : - Group I ( sequential therapy ) : Patients receive daunorubicin IV 30 minute day 1-3 , cytarabine IV continuously day 1-7 , oral PKC412 twice daily day 8-21 absence disease progression unacceptable toxicity . - Group II ( concurrent therapy ) : Patients receive daunorubicin cytarabine group I oral PKC412 twice daily day 1-7 15-21 absence disease progression unacceptable toxicity . In group , patient evaluate day 28 . Patients persistent disease receive second induction course comprise daunorubicin IV 30 minute day 1 2 , cytarabine IV continuously day 1-5 , oral PKC412 schedule assign treatment group . Patients complete response course 1 course 2 proceed consolidation therapy . - Consolidation therapy : Patients group receive high-dose cytarabine IV 3 hour twice daily day 1 , 3 , 5 oral PKC412 schedule assign treatment group . Treatment repeat every 28-42 day 3 course absence disease progression unacceptable toxicity . After completion consolidation therapy , patient group continue receive PKC412 alone , accord assign treatment group , every 28-42 day 3 year absence disease progression unacceptable toxicity . Patients follow every 3 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute myeloid leukemia ( AML ) Newly diagnose disease No history newly diagnose myelodysplastic syndrome , history myeloproliferative disease , secondary AML No CNS malignancy PATIENT CHARACTERISTICS : Age 18 60 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Not specify Hepatic AST ALT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN No active viral hepatitis Renal Creatinine ≤ 1.5 time ULN No chronic renal disease Cardiovascular Ejection fraction ≥ 50 % MUGA echocardiogram No congestive heart failure No myocardial infarction within past 6 month No poorly control hypertension No cardiovascular disease Pulmonary No pulmonary infiltrate , include suspect infectious Patients pulmonary infection whose clinical symptom resolve eligible provide residual pulmonary infiltrates chest xray Other No gastrointestinal impairment disease would preclude absorption study drug No uncontrolled diabetes No active uncontrolled infection No disease , except carcinoma situ , would preclude study participation No severe uncontrolled medical condition would preclude study participation HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy At least 5 day since prior growth factor No concurrent biological response modifier Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy except radiation castration No concurrent radiotherapy Surgery More 14 day since prior surgical procedure except central venous catheter placement minor procedure ( e.g. , skin biopsy ) Other More 30 day since prior investigational agent No concurrent anticancer agents No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>